immune aberrations in cancer patients
Cancer patients often exhibit immunosuppression and thereby decreased immunological recognition of the tumour [1] . This is manifested by defective proliferation and function of lymphocytes infiltrating the tumour. The T-cell anergy, however, appears to be reversible, and therapeutic approaches can potentially restore the function of the tumour-infiltrating lymphocytes [2] .
Tumours overcome the immune machinery by several mechanisms, including secretion of tumour-derived factors (such as immunosuppressive cytokines), expression of membrane-associated molecules and serine proteases. The genetic instability of cancer cells also facilitates immune escape through the downregulation of their antigen-processing machinery or upregulation of immunosuppressive factors, receptors and ligands. Tumour-induced immune suppression increases with tumour burden, and patients with bulky disease are typically less responsive to immunization [1, 3] . It is therefore likely that immunotherapy may be most clinically effective when used as adjuvant therapy or before onset of advanced disease.
immunosuppressive cells and immunosuppressive mechanisms
The essential cellular components involved in tumourassociated immunosuppression include regulatory T cells, myeloid-derived suppressor cells (MDSC; also called inhibitory macrophages or immature myeloid cells) and invariant natural killer cells (iNKT) (Figure 1 ).
regulatory T-cells
Regulatory T-cells, or Tregs, are a population of T cells that negatively regulate the activation of other T cells. In healthy individuals Treg constitute 5-6% of the CD4+ T-cell population. Treg have the function of maintaining the immunological self-tolerance by actively suppressing selfreactive lymphocytes as well as preventing an uncontrolled immune response against foreign antigens [4] . It has been demonstrated that a high frequency of Tregs in the peripheral blood of cancer patients may induce peripheral tolerance of tumour cells [5] . The intra-tumoural accumulation of Treg cells has also been associated with poor prognosis in several tumour types such as ovarian and gastric carcinomas in humans [6] . Treg cells constitutively express the receptors CD25, CTLA-4, OX-40 and GITR, characteristic of an activated phenotype [7] . The transcription factor FoxP3 is currently the most specific marker for the regulatory lineage [8] .
immunosuppressive mechanisms of regulatory T-cells
It is now well established that Treg cells are endowed with regulatory properties affecting both priming and the effector phase of immune cells [9] . Natural Tregs can inhibit T-cell response through membrane-bound mechanisms that include the surface molecules CTLA-4, membrane-bound transforming growth factor (TGF)-b and generation of pericellular adenosine [10] . Additionally, adaptive Tregs can secrete immunosuppressive cytokines like interleukin (IL)-10 and TGF-b.
myeloid-derived suppressor cells
MDSC are a recent finding and very little is known about their phenotype and function in humans. Nevertheless, the existence and expansion of different MDSC subsets with suppressive activity in cancer patients has been clearly demonstrated. MDSC arise from haematopoietic progenitor cells. Under conditions favouring immunosuppression and high levels of tumour-derived factors, MDSC are mobilized into the circulation, lymphoid organs and tumour microenvironment. This heterogeneous population not only inhibits activation and proliferation but also induces apoptosis of tumour-specific T cells. [13] . At higher doses cyclophosphamide causes lymphopenia and the recovery phase from lymphopenia has been suggested to be the most effective time point for administration of immunotherapy [14] . A single dose of cyclophosphamide as pre-conditioning has been used in studies with the BLP25 cancer vaccine that targets the antigen MUC1 expressed on many solid tumours including non-small-cell lung cancer and prostate cancer (reviewed in [15] ). In recent studies continuous, uninterrupted (metronomic) low doses of cyclophosphamide have been evaluated with the intention of depleting or inhibiting CD4+CD25+ regulatory T cells [16, 17] .
Gemcitabine is a pyrimidine nucleoside analogue which is used in the treatment of several solid tumours. Human and mouse studies have demonstrated that certain effects of gemcitabine can be conducive to use in combinatorial approaches with cancer vaccines. In mice, gemcitabine is known to affect antibody production without affecting antigen-specific T-cell stimulation. Our unpublished observations indicate that the number of Tregs in pancreatic cancer patients who receive vaccine together with gemcitabine is decreased. Gemcitabine may serve to prime immune responses against tumour-associated antigens since its tumour lytic effects may release a large number of tumour antigens which may be processed and presented by antigen-presenting cells in the vicinity. Treatment of advanced colorectal cancer patients with gemcitabine followed by FOLFOX and immunomodulation by GM-CSF and IL-2 significantly improved response rates and time to tumour progression [18] .
5-Fluorouracil (5-FU) is a fluoropyrimidine used in neo-adjuvant therapy, post-operative adjuvant treatment and treatment of metastatic solid tumours. Studies in vitro and using animal models have indicated that 5-FU can increase antigen uptake by dendritic cells, increase expression of heat-shock proteins, thereby facilitating antigen presentation, as well as upregulate expression of Fas and ICAM on tumour cells, consequently increasing the recognition of tumour cells by cytotoxic T lymphocytes (CTL). In clinical trials 5-FU has been used as a part of the FOLFOX course of therapy in an immunomodulatory regimen [18] . In another small Phase I/II study, patients with primary metastatic colorectal cancer received three cycles of chemotherapy based on 5-FU and irinotecan followed by vaccination with a carcinoembryonic antigen (CEA)-derived peptide vaccine and one of three immunological adjuvants. Of the 12 patients who completed three cycles of the treatment, there were five complete responses, one partial response, five with stable disease and six with progressive disease. Eight patients (47%) showed elevation of vaccine-specific CTL [19] .
depleting Tregs by targeting the IL-2 receptor: clinical studies with OntakÒ
OntakÒ or denileukin diftitox, is a novel fusion protein between the IL-2 and diphtheria toxin. The protein can bind to the IL-2 receptor (CD25) and introduce the diphtheria toxin into the cells expressing the receptor, thereby killing them. Ontak was originally developed against CD25-expressing T-cell lymphoma, but has subsequently been shown to be effective against B-cell malignancies which have little or no expression of CD25 (reviewed in [20] ). A recent study has demonstrated that Ontak can deplete human Tregs in vitro as well as murine Tregs in vitro and in vivo [21] . A single intraperitoneal injection of Ontak reduced the frequency of Tregs within 24 hours and lasted up to 10 days. Ontak also increased the immune response to a poxvirus-based CEA vaccine. The ability of Ontak to deplete human Tregs in vivo was demonstrated in a limited study with four (two ovarian, one breast and one lung cancer) patients, all of whom received a single infusion of Ontak [22] . Comparison of peripheral blood T-cell populations, before and 1 week after Ontak infusion demonstrated a statistically significant decrease in the number of CD4+CD25+ cells and a concomitant increase in CD3+IFNc+ cells. FoxP3 is a reliable marker of regulatory T cells and in one patient tested, the levels of FoxP3 mRNA in the CD4+CD25+ population was statistically decreased following Ontak infusion. In another study, the immune responses of seven patients who received a single dose of Ontak prior to vaccination with tumour RNA-transfected dendritic cells, was compared with four patients who received the vaccine alone. A 16-fold increase in immune responses was noted in patients who received the combination of Ontak and the vaccine compared with those who received the vaccine alone [23] . Similar results were also noted by Mahnke et al. [24] in a study examining the effects of Ontak on vaccine-induced immune responses in melanoma patients. Seven stage IV melanoma patients received Ontak followed by vaccination with peptides corresponding to MART-1 and gp100 antigens. The results were similar to the previous study by Dannull et al. [23] and a significant decrease in the numbers of Tregs were observed that lasted up to 20-24 days. Additionally, 90% of the patients had increased T-cell responses to the melanoma peptides. The only contradictory data are from the study by Attia et al. [25] which reported that administration of Ontak to melanoma patients did not affect their clinical prognosis or the numbers of circulating Tregs.
clinical studies with CTL-associated antigen-4 blockage CTLA-4 is a homologue of CD28 and a member of the immunoglobulin superfamily. It is a potent inhibitor of T cells and is involved in mediating T-cell anergy and tolerance. Resting T cells have very low or no expression of CTLA-4, but its expression is greatly enhanced following T-cell activation. Regulatory T cells constitutively express CTLA-4. CTLA-4 can suppress immunity through different mechanisms, the most direct of which is a greater affinity than the positive costimulatory molecule CD28 for binding to B7-1 and B7-2, along with transmission of a cell-intrinsic negative signal that inhibits T-cell activation. Engagement of CTLA-4 decreases Tcell proliferation, cytokine production, particularly IL-2, and limits cell migration.
Ipilimumab, developed by Bristol-Myers Squibb and Medarex and tremelimumab, developed by Pfizer, are two fully human monoclonal antibodies that block CTLA-4. Both antibodies have now been extensively tested in clinical trials. There is clear evidence that these agents that mediate their action by blocking the inhibitory receptor on T cells can have a therapeutic effect in a wide variety of solid tumours. Melanoma is the disease in which these agents have been tested most extensively, but trials have also been performed with prostate, renal cell and ovarian cancer patients. The review by Cranmer and Hersh [26] provides a detailed overview of the clinical trials performed with these two agents. What emerges is that both antibodies have demonstrated clinical efficacy as monotherapy as well as in combination with chemotherapeutic agents and/or cancer vaccines. The time kinetics of response is rather different, however, from conventional chemoradiotherapy, and several weeks may lapse before one sees the clinical effect of these agents. Toxicity and adverse effects of these antibodies can be empirically divided into two categories. The typical adverse effects of monoclonal antibody therapy are generally mild and self-limiting and include febrile episodes, injection-site reactions, fatigue etc. The more severe toxicity is associated with the so-called 'immune breakthrough events' and arises from potential immunopathological reactivity to normal tissues and organs. Of these, grade 3-4 enterocolitis and gastrointestinal inflammatory disease is the most common. Others include hypophysitis, dermatitis, uveitis, hepatitis, nephritis and thyroiditis. The adverse effects have been significant to the extent that there have been associated deaths or the need to discontinue therapy because of unacceptable toxicity. It is hoped that better control of the pharmacokinetics of these agents, improved dosing schedules and appropriate management strategies for toxicities will increase the clinical utility of these agents in the future.
conclusion
The therapeutic approaches discussed above provide a new paradigm in cancer therapy (Figure 2 ). Rather than depend on cytotoxic drugs and radiation in a battle of attrition against tumour cells, it is now possible to rework the immune system to overcome the aberrations induced by the tumour cells. The resultant immune response may in itself provide a therapeutic effect.
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